Figure S3.
MAZ51 reduces post-stroke dural and cervical lymph node lymphatic vessel area. (A and B) Quantitation of average Lyve-1+ vessel area near the COS (A) and SSS (B) of dural lymphatic vessels after either control or MAZ51 treatments between sham and tMCAO (n = 6 mice per group; mean ± SEM, *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001, one-way ANOVA). (C) Quantitation of average Lyve-1+ vessel area within dCLNs. (n = 6 mice per group; mean ± SEM, ****P ≤ 0.0001, one-way ANOVA). Source data are available for this figure: SourceData FS3.

MAZ51 reduces post-stroke dural and cervical lymph node lymphatic vessel area. (A and B) Quantitation of average Lyve-1+ vessel area near the COS (A) and SSS (B) of dural lymphatic vessels after either control or MAZ51 treatments between sham and tMCAO (n = 6 mice per group; mean ± SEM, *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001, one-way ANOVA). (C) Quantitation of average Lyve-1+ vessel area within dCLNs. (n = 6 mice per group; mean ± SEM, ****P ≤ 0.0001, one-way ANOVA). Source data are available for this figure: SourceData FS3.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal